Search

Hematology and oncology, pacemakers for EU HTA

EHA’s Martin Kaiser, right, addressing his fellow panelists. Left to right: Brian Cuffel (Bayer), Caroline Pothet (EMA), Roisin Adams (HTA CG), Bernhard Wörmann (DGHO) and Elisabeth de Vries (ESMO).

Read more

A Special Coach for the Cantera 2024

A unique tutorial for young hematologists, co-sponsored by the EHA Lymphoma Group and the Fondazione Italiana Linfomi. DatesMay 14 to May 17, 2024. LocationLecce, Italy. TopicHow the utilization of cellular therapy strategies looks for lymphomas in 2024.

Read more

Call for interest — new La Cantera event

The call for interest is closed at 23:59 on November 30, 2024. In 2025, EHA will provide funding for a new La Cantera coaching event.

Read more

Community and Stakeholder Committee call for interest

The Community and Stakeholder Committee (CSC) serves as an advisory body to the EHA Board and works closely with the EHA Office and other committees.

Read more

Fellowships and Grants Committee call for interest

The Fellowships and Grants Committee is responsible for assigning EHA funding to talented researchers. This year, we are looking for two new committee members.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more